SEMA7A and metabolic dysfunction-associated steatotic liver disease: To examine whether SEMA7A mutations contribute to the development of NAFLD in humans, we performed exon sequencing of SEMA7A (Supplemental Table 1; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.154113DS1) in 470 patients with biopsy-proven NAFLD (13).